Biogen Inc
NASDAQ: BIIB
$199.36
-$2.08 (-1.0%)
Closing Price on September 20, 2024
BIIB Articles
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
Alkermes saw its shares make a handy gain to start off the week, after the firm announced that it has entered into a global license agreement with Biogen.
Published:
Last Updated:
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.
Published:
Last Updated:
The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include AMD, Apple, Biogen, Capital One, Chipotle Mexican Grill, General Motors and 3M.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Biogen, Equifax, Foot Locker, General Electric, NVIDIA, Rio Tinto and Roku.
Published:
Last Updated:
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Biogen, Carbonite, Celgene, Emerson Electric, Kinder Morgan, Netflix and UnitedHealth.
Published:
Last Updated:
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous report, and short interest in all the selected biotech stocks increased.
Published:
Last Updated:
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include AMD, Biogen, Capital One, Intuit, Jinko Solar, Micron Technology, Albermarle and Alnylam Pharmaceuticals.
Published:
Last Updated: